DSM502|2426616-55-7|-陌孚医药/Medlife

您当前的位置：

DSM502

目录号: PL03266 纯度: ≥99%

CAS No. :2426616-55-7

商品编号	规格	价格	会员价
PL03266-5mg	5mg	¥4945.45	请登录
PL03266-10mg	10mg	¥7912.73	请登录
PL03266-50mg	50mg	询价	询价
PL03266-100mg	100mg	询价	询价
PL03266-10mM*1mLinDMSO	10mM*1mLinDMSO	¥5440.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	DSM502
英文名称	DSM502
英文别名	1H-Pyrrole-2-carboxamide, N-cyclopropyl-3-methyl-4-[[6-(trifluoromethyl)-3-pyridinyl]methyl]-;DSM502
Cas No.	2426616-55-7
分子式	C₁₆H₁₆F₃N₃O
分子量	323.31
包装储存	Powder -20°C 3 years；In solvent -80°C 6 months

产品详情	DSM502 是一种基于吡咯的二氢乳清酸脱氢酶 (DHODH) 抑制剂。DSM502 对 Plasmodium DHODH 和 Plasmodium 寄生虫表现出纳摩尔级效力，对哺乳动物 DHODH 没有抑制作用。
生物活性	DSM502 is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM502 exhibits nanomolar potency againsts Plasmodium DHODH and Plasmodium parasites, with no inhibition of mammalian DHODHs.
性状	Solid
IC50 & Target[1][2]	IC50: 20 nM (P. falciparum DHODH), 16 nM (P. vivax DHODH)
体外研究(In Vitro)	DSM502 shows inhibitory activity against P. falciparum DHODH ( Pf DHODH, IC50=20 nM), P. vivax DHODH ( Pv DHODH, IC50=14 nM) and Pf 3D7 cells (EC50=14 nM), with no inhibition of the human enzyme. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	DSM502 (10 and 50 mg/kg; p.o. once daily for 4 days) results in 97% parasite clearance in confirmatory SCID study compared to 85% clearance in the GSK study. DSM502 (18.3 and 50 mg/kg; a single p.o.) exhibits high oral bioavailability (>100%, >100%), apparent t 1/2 (2.6, 3.6 h) and C max (8.4, 42.3 μM) in mice. DSM502 (2.8 mg/kg; a single i.v.) exhibits apparent t 1/2 (2.8 h), plasma clearance (26.1 mL/min/kg), and V ss (1.2 L/kg) in mice. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；In solvent -80°C 6 months
参考文献	[1]. Kokkonda S, et, al. Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria. J Med Chem. 2020 May 14;63(9):4929-4956. [2]. Palmer MJ, et, al. Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series. J Med Chem. 2021 May 13;64(9):6085-6136.

溶解度数据	In Vitro: DMSO : 250 mg/mL (773.25 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation